Johnson & Johnson Vision (NYSE:JNJ) announced today that it received FDA 510(k) clearance and CE mark for its Veritas vision system.
Santa Ana, Calif.–based Johnson & Johnson Vision’s next-generation Veritas phacoemulsification system is designed to allow surgeons to guide through any lens density with less surge and more stability. It also incorporates advancements in ergonomics to enhance usability during cataract surgery, according to a news release.
Veritas’ approvals in the U.S. and Europe follow recent FDA nods for J&J Vision’s Tecnis Eyhance and Tecnis Eyhance Toric II intraocular lens for treating cataract patients, the company said.
Johnson & Johnson Vision intends to begin the full commercial launch of the Veritas system around the globe later this year, the company said.
“While the phacoemulsification technique has been used successfully for decades, ease of use continues to be the unmet need with cataract surgeons,” J&J Vision CMO & global head of clinical & medical affairs Dr. Rajesh K. Rajpal said in the release. “Every aspect of Johnson & Johnson Vision’s new Veritas system was designed to give surgeons an excellent user experience – optimizing features for safety and efficiency, with improvements in two main areas: fluidics and ergonomics.”